Quick Answer
Jasper Therapeutics, Inc. reported Operating Income of -$83.88 million for fiscal year 2025.
Jasper Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$83.88M | -10.0% |
| 2024 | -$76.24M | -10.7% |
| 2023 | -$68.86M | -34.5% |
| 2022 | -$51.20M | -39.0% |
| 2021 | -$36.83M | -1370.1% |
| 2021 | $2.90M | +114.0% |
| 2020 | -$20.68M | -813.2% |
| 2019 | $2.90M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.17M | +3.6% | +29.2% |
| June 30, 2025 | -$27.08M | -69.3% | -24.2% |
| March 31, 2025 | -$21.80M | -44.7% | -9.6% |
| September 30, 2024 | -$19.89M | -2.7% | -24.4% |
| June 30, 2024 | -$15.99M | +10.3% | -6.1% |
| March 31, 2024 | -$15.07M | -8.1% | +22.2% |
| September 30, 2023 | -$19.36M | -52.4% | -8.6% |
| June 30, 2023 | -$17.83M | -49.0% | -27.8% |
- Jasper Therapeutics, Inc. showed a decrease of -10.0% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Jasper Therapeutics, Inc.’s operating income has declined by 2992.5% (from $2.90 million to -$83.88 million).
- The most recent figure is from Jasper Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: